Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Nature 526 , 666671 (2015)
The researchers noted that compared with the control group, the epithalamin-treated patients exhibited [10]: Decelerated aging of the cardiovascular system Decreased rate of cardiovascular mortality and cardiovascular failure (-50%) Less age-associated impairment of physical endurance Normalized circadian rhythm for melatonin production Normalized circadian rhythm for lipid (fats) and carbohydrate metabolism Lower rate of mortality (-28%) The follow-up study on long-term epithalamin treatment represents strong evidence of eptithalons favorable safety profile and relative absence of notable epithalon side effects
Any therapeutic use occurs under physician supervision as off-label research application requiring comprehensive informed consent, medical monitoring, and understanding that the peptide is not an approved pharmaceutical agent
According to available research, the two most effective licensed treatments available currently are Wegovy and Mounjaro
